Oxford Nanopore Technologies PLC (ONTTF)
OTHER OTC:ONTTF
ONTTF Stock Chart & Stats
$1.46
--
Market closed
$1.46
--
Day’s Range― - ―
52-Week Range$1.27 - $3.34
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$1.50B
Enterprise Value$1.01B
Total Cash (Recent Filing)$255.30M
Total Debt (Recent Filing)$41.50M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Aug 19, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding972,930,360
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio1.37
Price to Book (P/B)2.66
Price to Sales (P/S)5.51
P/FCF Ratio-18.61
Enterprise Value/Market Cap0.67
Enterprise Value/Revenue4.50
Enterprise Value/Gross Profit7.67
Enterprise Value/Ebitda-9.54
Forecast
1Y Price Target
$2.65Price Target Upside81.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)$3.62M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthRe-accelerating top-line and broad-based regional growth indicate improving commercial traction and higher installed base. Durable demand growth supports recurring consumables sales and strengthens unit economics, making revenue more sustainable as the business shifts into higher-value applied markets.
Gross Margin QualityHigh and improving gross margins reflect a consumables-heavy model and pricing power in sequencing reagents and flow cells. Structural margin tailwinds (recycling, capex-first pricing and mix shift to applied/clinical customers) increase operating leverage as revenue scales, aiding sustainable profitability.
Balance Sheet StrengthLow leverage and a sizable cash balance provide a durable financial buffer to fund the path to breakeven and support R&D and capex-first deployments. Conservative balance-sheet positioning reduces refinancing risk and gives management flexibility to execute strategic product transitions.
Bears Say
Cash Burn & ProfitabilityPersistent negative operating and free cash flow, with material losses and repeated cash burn, mean the company remains dependent on external funding until breakeven. Continued losses erode equity and raise financing and execution risk if revenue or margin progress slips versus plan.
Product Roadmap RiskDelays and pauses (PromethION timing, P2 Solo discontinuation, ElysION pause) postpone anticipated revenue and margin contributions, increase conversion risk for device transitions, and require sustained investment. Such execution slippage can stretch the timeline to scale and profitability.
Regional / Regulatory HeadwindsStructural market access limits and rising local competition in APAC/China can curtail growth in a large addressable market, creating persistent backlog, delayed recognition and increased commercial friction. These constraints materially raise execution risk for sustained international expansion.
Oxford Nanopore Technologies PLC News
ONTTF FAQ
What was Oxford Nanopore Technologies PLC’s price range in the past 12 months?
Oxford Nanopore Technologies PLC lowest stock price was $1.27 and its highest was $3.34 in the past 12 months.
What is Oxford Nanopore Technologies PLC’s market cap?
Oxford Nanopore Technologies PLC’s market cap is $1.50B.
When is Oxford Nanopore Technologies PLC’s upcoming earnings report date?
Oxford Nanopore Technologies PLC’s upcoming earnings report date is Aug 19, 2026 which is in 57 days.
How were Oxford Nanopore Technologies PLC’s earnings last quarter?
Oxford Nanopore Technologies PLC released its earnings results on Mar 02, 2026. The company reported -$0.093 earnings per share for the quarter, the consensus estimate of -$0.093 by $0.
Is Oxford Nanopore Technologies PLC overvalued?
According to Wall Street analysts Oxford Nanopore Technologies PLC’s price is currently Undervalued.
Does Oxford Nanopore Technologies PLC pay dividends?
Oxford Nanopore Technologies PLC does not currently pay dividends.
What is Oxford Nanopore Technologies PLC’s EPS estimate?
Oxford Nanopore Technologies PLC’s EPS estimate is -0.08.
How many shares outstanding does Oxford Nanopore Technologies PLC have?
Oxford Nanopore Technologies PLC has 972,930,360 shares outstanding.
What happened to Oxford Nanopore Technologies PLC’s price movement after its last earnings report?
Oxford Nanopore Technologies PLC reported an EPS of -$0.093 in its last earnings report, expectations of -$0.093. Following the earnings report the stock price went down -16.535%.
Which hedge fund is a major shareholder of Oxford Nanopore Technologies PLC?
Currently, no hedge funds are holding shares in ONTTF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oxford Nanopore Technologies PLC Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$2.65 (81.51% Upside)
$2.65 (81.51% Upside)
Insider Transactions
Bought Shares
Worth $132.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.08%
12-Months-Change
Fundamentals
Return on Equity
-29.43%
Trailing 12-Months
Asset Growth
-15.57%
Trailing 12-Months
Company Description
Oxford Nanopore Technologies PLC
Oxford Nanopore Technologies plc, founded in 2005 and originally known as Oxford NanoLabs Limited before its name change in May 2008, is a United Kingdom-based enterprise that specializes in developing and commercializing an innovative system for analyzing diverse molecular structures through nanopore-based sensing. Its product range features a variety of devices, including the portable MinION for sequencing deoxyribonucleic acid and ribonucleic acid, and the MinION Mk1C, which integrates basecalling, data analysis, touchscreen controls, and wireless connectivity. For benchtop operations, the company offers the GridION, capable of running and analyzing up to five MinION or Flongle flow cells, as well as the GridION Mk1 nanopore sequencer. High-yield sequencing is made accessible with the PromethION 2 Solo and PromethION 2, while the PromethION 24 and PromethION 48 provide benchtop nanopore sequencers for multiple users to achieve multi-sample and multi-experiment results. Further complementing these devices are Flongle, an adapter for MinION or GridION units, and VolTRAX, a USB-powered tool designed to automate laboratory processes preceding nanopore sequencing. The company also provides a suite of software solutions: MinKNOW facilitates data acquisition, real-time analysis and feedback, local basecalling, and data streaming; specialized Basecalling tools pinpoint the identity and sequence of bases on DNA/RNA molecules; EPI2ME is a cloud-based platform for comprehensive, real-time analysis of nanopore data; and EPI2ME Labs offers bioinformatics support to help users refine their skills and confidence in analyzing their sequencing data. Additionally, Oxford Nanopore Technologies is actively developing new products such as MinION Mk1D, Ubi, Plongle, and SmidgION. All of its products are available for purchase online.
ONTTF Stock 12 Month Forecast
Average Price Target
$2.65
▲(81.51% Upside)
Avacta Group plc
―
Bioventix
―
Oxford BioDynamics
―
4basebio UK Societas
―
Aptamer Group Plc
―
Ownership Overview
0.08% Insiders
2.44% Mutual Funds
0.01% Other Institutional Investors
93.87% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---